Chemoinformaics analysis of Isoancistrocladine
| Molecular Weight | 407.51 | nRot | 4 |
| Heavy Atom Molecular Weight | 378.278 | nRig | 22 |
| Exact Molecular Weight | 407.21 | nRing | 4 |
| Solubility: LogS | -6.368 | nHRing | 1 |
| Solubility: LogP | 5.053 | No. of Aliphatic Rings | 1 |
| Acid Count | 0 | No. of Aromatic Rings | 3 |
| Base Count | 1 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 59 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 30 | No. of Aromatic Carbocycles | 3 |
| nHetero | 5 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 29 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 25 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 1 | No. of Arom Atom | 16 |
| No. of Oxygen atom | 4 | No. of Arom Bond | 17 |
| nHA | 5 | APOL | 65.395 |
| nHD | 2 | BPOL | 34.871 |
| QED | 0.627 |
| Synth | 3.563 |
| Natural Product Likeliness | 1.664 |
| NR-PPAR-gamma | 0.061 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.839 |
| Pgp-sub | 0.877 |
| HIA | 0.011 |
| CACO-2 | -5.272 |
| MDCK | 0.0000208 |
| BBB | 0.106 |
| PPB | 0.875512 |
| VDSS | 1.094 |
| FU | 0.0624078 |
| CYP1A2-inh | 0.364 |
| CYP1A2-sub | 0.976 |
| CYP2c19-inh | 0.571 |
| CYP2c19-sub | 0.847 |
| CYP2c9-inh | 0.097 |
| CYP2c9-sub | 0.851 |
| CYP2d6-inh | 0.537 |
| CYP2d6-sub | 0.931 |
| CYP3a4-inh | 0.192 |
| CYP3a4-sub | 0.916 |
| CL | 3.531 |
| T12 | 0.105 |
| hERG | 0.834 |
| Ames | 0.508 |
| ROA | 0.846 |
| SkinSen | 0.078 |
| Carcinogencity | 0.032 |
| EI | 0.008 |
| Respiratory | 0.891 |
| NR-Aromatase | 0.879 |
| Antiviral | Yes |
| Prediction | 0.680884 |